Corona was relieved by the announcement of the Indian Council of Medical Research (ICMR).
According to the ICMR, considering the situation, the antidote may not be available in India much earlier than expected.
Dr. Balaram Varghese, Director General, Indian Council of Medical Research (ICMR), said that it takes 8-9 months for a vaccine to complete the third or final stage of a human trial.
However, if the government decides, emergency approval may be considered. This was reported by the news agency PTI.
The results of the first round of human trials of Covaxin, a coronavirus made in India, have recently come to light.
According to observers, these results are quite hopeful! Covaxin’s second round of human trials has already begun.
It is known that Covaxin will be applied experimentally to a total of 1,100 volunteers in two phases.
The Indian Council of Medical Research (ICMR) has selected a total of 12 institutes for the trial, including the Nizam Institute of Medical Sciences in Hyderabad, AIIMS in Delhi and Patna.
On the other hand, the trial of the first episode was successfully completed by the Ahmedabad-based pharmaceutical company Zydus Cadila’s coronary DNA vaccine (ZyCov-D).
Zydus Cadila (Zydus Cadila) According to the rules of the Corona Ticker (ZyCov-D) trial, three pairs of antidotes should be given every 28 days.
Volunteers were monitored for 28 days after vaccination.
The trial of the second episode of Ticker is also to be conducted under the same rules.
India Biotech’s Covaxin and Zydus Cadillac Corona vaccine ZyCov-D’s second phase of the human trial is now nearing completion.
The news agency PTI quoted ICMR on Wednesday as saying that considering the current situation, the two ticks are being considered for “emergency approval”.
Urgent approval of any antidote can be considered if the Indian Government so desires.
